Gordon Wong, D.Phil.
Vice President, New Ventures Biogen Idec

Dr. Gordon Wong has been a Vice President in Biogen Idec’s corporate venture group, New Ventures, since 2005. From 2002 to 2004, he was co-founder and Chief Scientific Officer (CSO) at Compound Therapeutics (re-named Adnexus Therapeutics in 2005), a protein engineering company focused on the design of therapeutic proteases and antibody like protein antagonists. From 1983 to 2000, Dr. Wong served in positions of staff and senior scientist, project leader, scientific fellow and senior director of research at Genetics Institute/Wyeth generating over 35 issued US patents and over 75 scientific publications. Dr. Wong graduated from Oxford University where he attended as a Rhodes Scholar receiving a D.Phil. in Biochemistry. Additionally he recently completed the Advanced Management Program at the Harvard Business School. Currently Dr. Wong sits on the board of CalciMedica and holds board observer seats with Cambria Pharmaceuticals, Inc. and Virdante Pharmaceuticals, Inc